Publications

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine

Featured

Publication Date:

November 2022

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis

Caregiver willingness to give TPT to children living with drug-resistant TB patients

Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing

A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282

A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Viral and Symptom Rebound in Untreated COVID-19 Infection

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

High Asymptomatic Carriage With the Omicron Variant in South Africa

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Educational antimicrobial stewardship programs in medical schools: a scoping review

HIV and ART related knowledge among newly diagnosed patients with HIV under the universal test-and-treat (UTT) policy in Johannesburg, South Africa

Persistent Symptoms among Frontline Health Workers Post-Acute COVID-19 Infection

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Trends in Cases, Hospitalization and Mortality Related to the Omicron BA.4/BA.5 Sub-Variants in South Africa

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study

Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Performance of the Abbott SARS-CoV-2 IgG serological assay in South African 2 patients. PLoS One

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and "Undetectable = Untransmittable": A Systematic Review.

A Failure to Disseminate Transformative Science - HIV Treatment as Prevention, 10 Years On

The Scientists' Collective 10-point proposal for equitable and timeous access to COVID-19 vaccine in South Africa.

A. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial

Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Is the Risk Really Shared? A Retrospective Analysis of Healthcare Costs of Patients With Type 2 Diabetes Mellitus on a Capitation Mode

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Proposed linezolid dosing strategies to minimize adverse events for treatment of extensively drug-resistant tuberculosis

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Perceived efficacy of HIV treatment-as-prevention among university students in Johannesburg, South Africa

Primary healthcare seeking behaviour of low-income patients across the public and private health sectors in South Africa

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Modelling costs at scale of community-based HIV self-testing programmes in Southern Africa at scale: An econometric cost function analysis across five countries

Antiretroviral hair levels, self-reported adherence, and virologic failure in second-line regimen patients in resource-limited settings

Optimal use of COVID19 Ag-RDT screening at border crossings to prevent community transmission: a modeling analysis

Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa

Costs of integrating HIV self-testing in public health facilities in Malawi, South Africa, Zambia and Zimbabwe

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa

Differentiated Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A Landscape Analysis. Global Health: Science and Practice

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Sanne I, Rosen S. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial

The revolving door of HIV care: Revising the service delivery cascade to achieve the UNAIDS 95-95-95 goals.

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Inpatient Care Costs of COVID-19 in South Africa's Public Healthcare System

Economic evaluation of differentiated service delivery models for HIV treatment in Lesotho: costs to providers and patients

A clinician's primer on epidemiology for COVID-19

Population density and basic reproductive number of COVID-19 across United States counties

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa

Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis

SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention

Community-based delivery of HIV treatment in Zambia: costs and outcomes

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

The Cost and Intermediary Cost Effectiveness of Oral HIV Self-Test Kit Distribution Across Eleven Distribution Models in South Africa

Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar

Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa

Health provider perspectives on the implementation of the same-day-ART initiation policy in the Gauteng province of South Africa

Role of data from cost and other economic analyses in healthcare decision-making for HIV, TB and sexual/reproductive health programmes in South Africa

Bringing Data Analytics to the Design of Optimized Diagnostic Networks in Low- and Middle-Income Countries: Process, Terms and Definitions. Diagnostics

Incidence and predictors of sexually transmitted infections among adult HIV-positive patients receiving antiretroviral therapy at Themba Lethu HIV clinic in Johannesburg, South Africa

CHRU’s scientific output and contribution

CHRU Publications

Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach

The lived experiences of Tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis

Contemporary Issues in Women's Health

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis

Performance of spirometry assessment at TB diagnosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial

Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral

Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19

Guiding equitable prioritisation of COVID-19 vaccine distribution and strategic deployment in South Africa to enhance effectiveness and access to vulnerable communities and prevent waste

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled tria

Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis

Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study

Operational characteristics of 30 lateral flow immunoassays used to identify COVID-19 immune response

Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study

Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study

Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.

The Role of Remdesivir in South Africa: Preventing COVID-19 Deaths Through Increasing Intensive Care Unit Capacity

Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial

Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus

Adaptation of WHO's generic tuberculosis patient cost instrument for a longitudinal study in Africa

Mapping the cervical cancer screening cascade among women living with HIV in Johannesburg, South Africa

Year

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co-infected patients in Ukraine

Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial

Antiretroviral initiation at ≥800 CD4+ cells/ mm 3 associated with lower HIV reservoir size

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Tuberculosis and Sexual and Reproductive Health of Women in Four African Countries

Rifapentine with and without moxifloxacin for pulmonary tuberculosis in people with HIV

The cost effectiveness and optimal configuration of HIV self-test distribution in South Africa: a model analysis

Caregiver willingness to give TPT to children living with drug-resistant TB patients

Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing

A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282

A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis

Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study

Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting

Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine

Viral and Symptom Rebound in Untreated COVID-19 Infection

Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine

Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts

High Asymptomatic Carriage With the Omicron Variant in South Africa

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial

Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial

Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis

Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionC

Educational antimicrobial stewardship programs in medical schools: a scoping review

HIV and ART related knowledge among newly diagnosed patients with HIV under the universal test-and-treat (UTT) policy in Johannesburg, South Africa

Persistent Symptoms among Frontline Health Workers Post-Acute COVID-19 Infection